NasdaqGM:LNTH
NasdaqGM:LNTHMedical Equipment

Reassessing Lantheus Holdings After a 27.6% Slide and Recent Share Price Rebound

Wondering if Lantheus Holdings is quietly turning into a bargain, or if the market already sees something you do not? Let us break down what the recent numbers are really saying about its value. The stock is down 27.6% over the last year and 25.8% year to date, but it has bounced 18.1% in the last month, a pattern that often signals investors are rethinking the story. That shift in sentiment comes as Lantheus continues to build on its diagnostics and radiopharmaceutical portfolio, including...
NasdaqCM:SBET
NasdaqCM:SBETHospitality

Is SharpLink Gaming Attractively Priced After 21.4% Year To Date Rebound?

Wondering if SharpLink Gaming at around $9.81 is a hidden value opportunity or a value trap? You are not alone; this stock has started to pop up on more radars lately. Over the last week the share price is up 3.2%, roughly matching its 3.0% gain over the past month, but the real eye catcher is the 21.4% return year to date after a tough 3 year slide of 74.1%. Recent headlines have focused on SharpLink Gaming's strategic push deeper into sports betting technology and partnerships with media...
NasdaqGS:DKNG
NasdaqGS:DKNGHospitality

Is DraftKings Stock Offering Value After a 196% Three Year Surge?

If you are wondering whether DraftKings at around $34 a share is a bargain or a bubble, you are not alone. This article walks through what the numbers really say about its value. Over the last month the stock is up 14.1%, but that comes after a choppy run, with the shares down 3.9% over the past week, 5.7% year to date, and 10.8% over the last year. The 3 year return still sits at an eye catching 196.7%. Those swings have been underpinned by ongoing state by state legalization and expansion...
NasdaqGS:EXLS
NasdaqGS:EXLSProfessional Services

How Investors May Respond To ExlService Holdings (EXLS) Buyback And AI‑Led Earnings Momentum

Earlier this month, ExlService Holdings completed a US$63.37 million repurchase of 1,551,970 shares at US$40.83 each from Orogen Echo LLC, alongside reporting a quarter of 12% revenue growth and 11% adjusted EPS growth powered by its data and AI offerings. At the same time, EXL’s full migration of its LifePRO Digital Suite to Amazon Web Services highlights how its AI-enabled, cloud-based platforms are reshaping life and annuity operations for global insurers. Next, we’ll explore how EXL’s...
NYSE:PRG
NYSE:PRGConsumer Finance

PROG Holdings (PRG): Valuation Check After Positive New Coverage From B. Riley Securities

B. Riley Securities just kicked off coverage on PROG Holdings, giving the stock a fresh spotlight and a clearly positive stance that could reshape how investors think about this underfollowed lender. See our latest analysis for PROG Holdings. That fresh coverage lands after a choppy stretch, with a recent 1 month share price return of 6.55 percent but a much weaker year to date share price return of minus 29.20 percent. Even so, the 3 year total shareholder return of 79.37 percent still...
NYSE:LEA
NYSE:LEAAuto Components

Lear (LEA) Valuation Check After Recent Share Price Momentum

Lear (LEA) has quietly outperformed the broader auto parts space over the past month, with the stock climbing about 14% as investors warm to its mix of seating scale and E-systems growth. See our latest analysis for Lear. Zooming out, Lear’s recent 1 month share price return of about 14% and strong year to date share price gain of roughly 28% suggest momentum is building, even though its 5 year total shareholder return remains modestly negative. If Lear’s move has you watching the auto cycle...
NasdaqGS:LIVN
NasdaqGS:LIVNMedical Equipment

LivaNova (LIVN): Reassessing Valuation After KeyBanc’s Overweight Initiation and Growth Outlook

KeyBanc just kicked off coverage on LivaNova (LIVN) with an Overweight call, highlighting what it sees as underappreciated growth from capital equipment cycles, share gains, better clinical data, and upcoming aura6000 commercialization. See our latest analysis for LivaNova. The upbeat initiation comes as LivaNova’s share price has climbed 34.66 percent year to date and delivered a 33.69 percent total shareholder return over the past year. This suggests momentum is building as investors...
NasdaqGS:TSHA
NasdaqGS:TSHABiotechs

Should Rett Breakthrough Status and Pivotal Trial Plan Require Action From Taysha Gene Therapies (TSHA) Investors?

Taysha Gene Therapies recently received FDA Breakthrough Therapy Designation for its Rett syndrome gene therapy candidate TSHA-102 and secured regulatory alignment on the pivotal REVEAL trial protocol, including a planned six-month interim analysis to support a future Biologics License Application. This combination of regulatory recognition and a clearly defined clinical pathway adds important validation to TSHA-102’s potential and clarifies how quickly the Rett program could progress toward...
NYSE:POST
NYSE:POSTFood

Post Holdings (POST): Valuation Check After New Debt Issue, Earnings Beat and $500m Buyback Plan

Post Holdings (POST) has given investors plenty to chew on lately, with fresh $1.3 billion senior notes, stronger than expected quarterly numbers, and a new $500 million buyback reshaping its capital playbook. See our latest analysis for Post Holdings. At around $100.83 per share, Post’s 1 month share price return has been modestly positive but its year to date share price return is still clearly negative. A 5 year total shareholder return in the mid 40 percent range shows the longer term...
NasdaqGS:CRWV
NasdaqGS:CRWVIT

US Stock Market Today: S&P 500 Futures Climb as Housing Strength Counters Inflation Jitters

The Morning Bull - US Market Morning Update Monday, Dec, 22 2025 US stock futures are pointing higher this morning, with E mini S&P 500 contracts up about 0.3 percent as investors juggle stronger housing data and stubborn inflation expectations. Existing home sales ticked up 0.5 percent in November to a nine month high, a sign that higher mortgage rates are not fully freezing the housing market. This matters for construction jobs and household wealth. At the same time, a key consumer...
NasdaqGS:GFS
NasdaqGS:GFSSemiconductor

Is CFO Shift And German Fab Aid Amid Nasdaq-100 Exit Altering The Investment Case For GlobalFoundries (GFS)?

GlobalFoundries recently appointed Sam Franklin as Chief Financial Officer, cementing leadership continuity as he moves from Interim CFO into the permanent role with broad responsibility for finance and operations. At the same time, GlobalFoundries is exiting the Nasdaq-100 while securing nearly €495 million in German government aid to expand its Dresden semiconductor facilities and deepen its position in power semiconductors and silicon photonics for AI data centers. Next, we’ll explore how...
NasdaqGM:SMMT
NasdaqGM:SMMTBiotechs

The Bull Case For Summit Therapeutics (SMMT) Could Change Following Ivonescimab’s HARMONi-3 Phase 3 Spotlight - Learn Why

Cantor Fitzgerald recently reiterated its Overweight rating on Summit Therapeutics while Barclays upgraded the stock to Equalweight, spotlighting ivonescimab’s planned late-2025 Biologics License Application submission and the pivotal global phase 3 HARMONi-3 lung cancer study expected in 2026. These endorsements underscore how ivonescimab and the HARMONi-3 program have moved to the center of the biotech conversation around late-stage oncology assets. With Summit Therapeutics’ shares...
NasdaqGS:TSLA
NasdaqGS:TSLAAuto

Electric Vehicles Update - Revolutionizing Tires With Sustainable Polymer Innovations

Emerging technologies in polymer compounds and silica reinforcements are significantly transforming the electric vehicle tire industry. The introduction of advanced materials like bio-based polymers is aimed at boosting performance while addressing regulatory demands for sustainability and consumer preferences for eco-friendly options. The focus on new tire design standards is catalyzed by the unique requirements of electric vehicles, including reduced rolling resistance and enhanced...
NYSE:JNJ
NYSE:JNJPharmaceuticals

Does Johnson & Johnson’s 2025 Rally Still Offer Value After Strong DCF and PE Signals?

Wondering if Johnson & Johnson is still a buy at around $206 a share, or if the easy gains are already behind it? This breakdown will help you decide whether the current price matches the company’s long term fundamentals. Despite a recent dip of 3.6% over the last week, the stock is still up 1.2% over the past month, 43.3% year to date and 46.4% over the last year, which indicates the market has been steadily re-rating J&J’s prospects. That momentum has been shaped by a stream of news, from...
NasdaqGS:CCB
NasdaqGS:CCBBanks

How Renewed Institutional Interest In Coastal Financial’s Earnings Outlook At Coastal Financial (CCB) Has Changed Its Investment Story

Earlier this week, Coastal Financial, a banking services provider focused on community banking, saw renewed investor interest as robust earnings growth forecasts drew fresh attention from institutional investors. This reaction highlights how confidence from large investors can reinforce market belief in Coastal Financial’s community banking business model and earnings potential. We’ll now examine how this renewed institutional confidence shapes Coastal Financial’s investment narrative and...